Combination antiviral therapy for measles
AssigneesThe Trustees of Columbia University in the City of New York, Cornell University
InventorsMatteo POROTTO, Anne MOSCONA, Christopher ALABI
Life of this patent
Estimating the term…
Abstract
Described herein are peptides, compositions, and method of treating measles or HIV infection with antiviral peptide conjugates comprising a fusion inhibitory peptide (FIP) conjugated to a C-terminal heptad repeat (HRC) peptide. Also described herein are soluble stabilized measles F proteins, compositions, and method of preventing measles infection with the stabilized F protein, which can be administered alone, or in combination with the antiviral peptide conjugates described herein.
Claims60
An antiviral peptide conjugate comprising a fusion inhibitory peptide (FIP) and a C-terminal heptad repeat (HRC) peptide (FIP-HRC).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A recombinant protein comprising a soluble stabilized measles F protein comprising an E445G mutation or comprising a E170G and a E455G double mutation.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.